Human target complement inhibitor protein mcr2-cd59 and its application

A fusion protein and complement receptor technology, applied in the field of fusion proteins, can solve the problems of affecting CD59 inhibitory activity, affecting complement inhibitor activity, and low inhibitory activity, and achieve excellent anti-adhesion/anti-inflammatory targeted inhibition effect, Crescent body/necrosis improvement, beneficial therapeutic effect

Active Publication Date: 2022-07-26
BEIJING COMPLEMENT THERAPEUTICS LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are still some technical problems in the inhibition of complement activity by the complement receptor 2 and CD59 fusion protein. For example, in comparison with the complement receptor 2 and DAF fusion protein, its inhibitory activity is not high, and CR2 and CD59 complement Different fusion orientations also significantly affected the inhibitory activity of CD59
Problems in the prior art suggest that the sequence and even the spatial conformation of the fusion protein is a key factor affecting the full activity of complement inhibitors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human target complement inhibitor protein mcr2-cd59 and its application
  • Human target complement inhibitor protein mcr2-cd59 and its application
  • Human target complement inhibitor protein mcr2-cd59 and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1. Preparation of mCR2-CD59 fusion protein and CR2-CD59 fusion protein

[0034] 1 Materials The expression vector was pEE14.1 (Lonza biologics); CHO cells were used for protein expression, and the culture medium was DMEM containing 10% fetal bovine serum, purchased from Invitrogen Company. Mouse anti-CD59 mAbs 1H4 and 1A10, mouse anti-human CR2 mAb 171, anti-goat erythrocyte IgM and all secondary antibodies were purchased from Sigma.

[0035] 2 methods

[0036] 2.1 Preparation of antiserum of rabbit anti-CHO cell membrane and human CD59 according to the literature Harlow, E., and Lane, D. Antibodies: a laboratory manual. Cold Spring Harbor Laboratory. Cold Spring Harbor, New York, USA. 1988:726. method to obtain.

[0037] 2.2 Construction of expression recombinant and protein expression cDNA structure The gene is formed by connecting the four N-terminal SCR units encoding CR2 and the sequence encoding the extracellular region of CD59. The complement inhibitor...

Embodiment 2

[0045] Example 2. Kinetic analysis of interaction between CR2 fusion protein and C3 ligand

[0046]Kinetic analysis of the interaction of the CR2 fusion protein with biotin-labeled C3dg (C3dg-biotin) was detected with a Surface Cytoplasmic Resonance (SPR) detection system (BIAcore 3000 instrument). Human C3dg-biotin (Guthridge, J.M., et al. Structural studies insolution of the recombinant N-terminal pair of short consensus / complementrepeat domains of complement receptor type 2 (CR2 / CD21) and interactions with its ligand C3dg. Biochemistry. 2001, 40(20): 5931–5941.) were injected onto the BIAcore streptavidin sensor chip at a rate of 2 μL / min for 20 min, and the buffer was 0.5× PBS (pH 7.4) (containing 0.5 g / L Tween20). The SPR signal acquired from the captured C3dg yielded BIAcore response units (range 250 to 500). The group without fusion protein was used as a control. After washing with 0.5×PBST (0.5g / LTween20) at 25°C at a flow rate of 25μL / min, the affinity of the CR2 ...

Embodiment 3

[0050] Example 3. Complement lysis assay

[0051] To determine the inhibitory activity against complement, 60%-80% confluent CHO cells were split with EDTA, washed twice with DMEM, and then resuspended in DMEM to a final concentration of 10 6 cells / mL. 100 mL / L rabbit anti-CHO cell membrane antiserum was added to the cell suspension, and the cells were sensitized for 30 min at 4°C. Antiserum was then discarded and cells were resuspended in NHS diluted in DMEM in a final volume of 50 μL or 100 μL. The cells were incubated at 37°C for 60 min, and finally the cell viability was measured by placental blue staining exclusion method (both live and dead cells were counted). The recombinant fusion protein was diluted with DEME and added to NHS and then to the CHO cell suspension. The final concentration was based on the lysis of control CHO cells in which 100 g / L NHS resulted in approximately 90% antibody sensitization. The complement-mediated inhibition of erythrocyte lysis assay...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a fusion protein of a complement receptor 2 variant and a complement inhibitor CD59 and an application of the fusion protein in the preparation of a drug for treating autoimmune diseases. The complement receptor 2 variant is a molecular modification obtained after computer modeling and amino acid substitution, and has higher ligand binding and dissociation rates and better ligand binding capacity than its wild-type sequence. The biological distribution experiment proves that the fusion protein provided by the present invention can rapidly and highly aggregate in the arthritis site after entering the rheumatoid arthritis mouse model, and has significant anti-adhesion / anti-inflammatory targeting inhibition effect. In the treatment of MRL / lpr lupus erythematosus mice, the fusion protein can significantly improve the survival rate of mice. Symptoms such as necrosis were significantly improved.

Description

technical field [0001] The invention discloses a fusion protein, which belongs to the technical field of polypeptides. Background technique [0002] The complement system is composed of more than 30 kinds of soluble protein molecules, which are part of the natural immune system. The complement system can be activated through 3 relatively independent and interconnected pathways, thereby exerting various biological effects such as opsonophagocytosis, lysis of cells, mediation of inflammation, immune regulation and clearance of immune complexes, including enhanced phagocytosis and enhanced phagocytosis. Chemotaxis of cells, increase of vascular permeability, neutralization of viruses, cytolysis, regulation of immune responses, etc. Complement activation and its deposition on target structures can also indirectly cause cellular or tissue destruction, producing complement activation products that mediate tissue damage at various points in the complement pathway. Inappropriate c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/85C12N5/10A61K47/64A61P19/02A61P37/02A61P29/00
CPCC07K14/70596C07K14/705A61K47/6425A61P19/02A61P37/02A61P29/00C07K2319/33
Inventor 唐晓敏杜兰英
Owner BEIJING COMPLEMENT THERAPEUTICS LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap